#United States #New York #Faruqi & Faruqi #RZLT #Rezolute

Faruqi & Faruqi, LLP Investigates Rezolute, Inc.

In a recent development, Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation focused on potential claims related to Rezolute, Inc. (NASDAQ: RZLT). This inquiry arises amidst significant losses reported by investors following disappointing results from the company's latest clinical trial.

On December 11, 2025, the share prices of Rezolute experienced a drastic decline when it became evident that the results of the Phase 3 sunRIZE clinical trial for its lead drug candidate, ersodetug, did not meet expectations. The trial aimed at treating congenital hyperinsulinism, a rare disorder characterized by excessive insulin production.

Disappointing Clinical Trial Results

The results from the sunRIZE trial were particularly disheartening, as the drug failed to achieve both its primary and key secondary endpoints. Although the highest dose exhibited some reductions in hypoglycemia events, these results were not statistically significant when compared to placebo. Such outcomes severely impacted investor confidence, leading to a sharp downturn in the company's stock value.

James (Josh) Wilson, a senior partner at Faruqi & Faruqi, is urging investors who have faced significant losses in Rezolute stock or options to come forward. The law firm has a history of representing investors in similar cases and has a proven track record of recovering hundreds of millions of dollars since its establishment in 1995.

Legal Rights for Investors

For those affected, it is crucial to understand your legal rights and options following these significant market movements. Faruqi & Faruqi encourages investors to reach out directly to Josh Wilson, who is prepared to assist them in navigating the legal landscape following these developments. Interested parties can contact him at 877-247-4292 or 212-983-9330 (Ext. 1310) for personalized advice.

As this investigation unfolds, details regarding the specific claims against Rezolute, Inc. will become clearer. The law firm is dedicated to keeping stakeholders informed and advocates for transparency in the securities market.

Conclusion

The investigation conducted by Faruqi & Faruqi represents an effort to address the significant concerns raised by investors following Rezolute's disappointing clinical trial results. As the firm continues its inquiry, affected investors are urged to seek legal counsel and remain vigilant about their rights.

For more information on the Rezolute investigation, visit Faruqi & Faruqi’s website or follow updates on various social media platforms. Protecting the interests of investors remains a top priority as this case develops.